BGLC vs. XGN, RNLX, PMD, DMTK, OPGN, FRES, ACON, NVTA, CNTG, and LH
Should you be buying BioNexus Gene Lab stock or one of its competitors? The main competitors of BioNexus Gene Lab include Exagen (XGN), Renalytix (RNLX), Psychemedics (PMD), DermTech (DMTK), OpGen (OPGN), Fresh2 Group (FRES), Aclarion (ACON), Invitae (NVTA), Centogene (CNTG), and Laboratory Co. of America (LH). These companies are all part of the "medical laboratories" industry.
BioNexus Gene Lab (NASDAQ:BGLC) and Exagen (NASDAQ:XGN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, community ranking, dividends, valuation, earnings, analyst recommendations, media sentiment, risk and institutional ownership.
BioNexus Gene Lab has higher earnings, but lower revenue than Exagen.
In the previous week, BioNexus Gene Lab and BioNexus Gene Lab both had 2 articles in the media. BioNexus Gene Lab's average media sentiment score of 1.44 beat Exagen's score of 0.92 indicating that BioNexus Gene Lab is being referred to more favorably in the media.
Exagen received 20 more outperform votes than BioNexus Gene Lab when rated by MarketBeat users.
Exagen has a consensus price target of $7.00, suggesting a potential upside of 258.97%. Given Exagen's higher probable upside, analysts plainly believe Exagen is more favorable than BioNexus Gene Lab.
18.9% of BioNexus Gene Lab shares are owned by institutional investors. Comparatively, 75.3% of Exagen shares are owned by institutional investors. 6.8% of BioNexus Gene Lab shares are owned by company insiders. Comparatively, 26.1% of Exagen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
BioNexus Gene Lab has a net margin of -27.24% compared to Exagen's net margin of -34.74%. BioNexus Gene Lab's return on equity of -30.74% beat Exagen's return on equity.
Summary
BioNexus Gene Lab and Exagen tied by winning 6 of the 12 factors compared between the two stocks.
Get BioNexus Gene Lab News Delivered to You Automatically
Sign up to receive the latest news and ratings for BGLC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BGLC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioNexus Gene Lab Competitors List
Related Companies and Tools
